{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:57:47Z","timestamp":1787954267836,"version":"build-2784847793"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objective<\/jats:title>\n<jats:p>To compare between current evidence of novel glycopeptides against vancomycin for the treatment of gram-positive bacterial infections.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methodology<\/jats:title>\n<jats:p>A systematic review and meta-analysis was done. Major databases were searched for eligible randomized control trials that assessed clinical success, microbiological success and safety profile of novel glycopeptides versus vancomycin for infections caused by gram-positive bacteria.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>This meta-analysis included eleven trials (7289 participants) comparing telavancin, dalbavancin and oritavancin with vancomycin. No differences were detected between novel glycopeptides and vancomycin for the treatment of skin and soft tissue infections (SSTIs) among modified intent-to-treat patients (OR: 1.04, CI: 0.92\u20131.17) as well as within the clinically evaluable patients (OR: 1.09, CI: 0.91\u20131.30). Data analysed from SSTIs, HAP and bacteremia studies on telavancin showed insignificant high clinical response in microbiologically evaluable patients infected with methicillin resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (MRSA) (OR: 1.57, CI: 0.94\u20132.62, <jats:italic>p<\/jats:italic>: 0.08) and in the eradication of MRSA (OR: 1.39, CI: 0.99\u20131.96, <jats:italic>P<\/jats:italic>:0.06). Dalbavancin was non-inferior to vancomycin for the treatment of osteomyelitis in a phase II trial, while it was superior to vancomycin for the treatment of bacteremia in a phase II trial. Data analysed from all trials showed similar rates of all-cause mortality between compared antibiotics groups (OR: 0.67, CI: 0.11\u20134.03). Telavancin was significantly related with higher adverse events (OR: 1.24, CI: 1.07\u20131.44, <jats:italic>P<\/jats:italic>: &lt;0.01) while dalbavancin and oritavancin were associated with significant fewer adverse events (OR: 0.73, CI: 0.57\u20130.94, <jats:italic>p<\/jats:italic>: 0.01; OR: 0.72, CI: 0.59\u20130.89, <jats:italic>p<\/jats:italic>: &lt;0.01 respectively).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Efficacy and safety profiles of both dalbavancin and oritavancin were the same as vancomycin in the treatment of gram-positive bacterial infections in different clinical settings, while telavancin might be an effective alternative to vancomycin in MRSA infections, but caution is required during its clinical use due to the high risk of adverse events, especially nephrotoxicity.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0260539","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T18:34:52Z","timestamp":1638210892000},"page":"e0260539","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy and safety of novel glycopeptides versus vancomycin for the treatment of gram-positive bacterial infections including methicillin resistant Staphylococcus aureus: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7813-0153","authenticated-orcid":true,"given":"Wissal","family":"Jame","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilgen","family":"Basgut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdikarim","family":"Abdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"issue":"2644","key":"pone.0260539.ref001","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1126\/science.102.2644.221","article-title":"Quantitative action of penicillin inhibitors from penicillin-resistant strains of staphylococci","volume":"102","author":"WW Spink","year":"1945","journal-title":"Science"},{"issue":"2","key":"pone.0260539.ref002","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1592\/phco.27.2.227","article-title":"Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections","volume":"27","author":"RH Drew","year":"2007","journal-title":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"},{"issue":"1","key":"pone.0260539.ref003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-0711-5-2","article-title":"Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States","volume":"5","author":"D Styers","year":"2006","journal-title":"Annals of clinical microbiology and antimicrobials"},{"issue":"2","key":"pone.0260539.ref004","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3201\/eid0702.010204","article-title":"The changing epidemiology of Staphylococcus aureus?","volume":"7","author":"HF Chambers","year":"2001","journal-title":"Emerging infectious diseases"},{"issue":"7","key":"pone.0260539.ref005","first-page":"376","article-title":"Trends in antimicrobial utilization at a tertiary teaching hospital during a 15-year period (1978\u20131992)","volume":"14","author":"R Pallares","year":"1993","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"3","key":"pone.0260539.ref006","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1128\/JCM.02187-13","article-title":"Report of the 13th vancomycin-resistant Staphylococcus aureus isolate from the United States","volume":"52","author":"BM Limbago","year":"2014","journal-title":"Journal of clinical microbiology"},{"issue":"5","key":"pone.0260539.ref007","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1086\/527392","article-title":"Vancomycin-resistant Staphylococcus aureus in the United States, 2002\u20132006","volume":"46","author":"DM Sievert","year":"2008","journal-title":"Clinical Infectious Diseases"},{"issue":"9","key":"pone.0260539.ref008","article-title":"Antimicrobial therapies for Gram-positive infections","volume":"9","author":"C Eades","year":"2017","journal-title":"Clin. Pharm"},{"issue":"12","key":"pone.0260539.ref009","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/j.clinthera.2015.11.007","article-title":"Beyond vancomycin: the tail of the lipoglycopeptides","volume":"37","author":"KP Klinker","year":"2015","journal-title":"Clinical therapeutics"},{"key":"pone.0260539.ref010","unstructured":"European Medicines Agency, Withdrawal of the marketing authorisation in the European Union. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/public-statement-vibativ-withdrawal-marketing-authorisation-european-union_en.pdf"},{"issue":"4","key":"pone.0260539.ref011","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/cid\/civ311","article-title":"Oritavancin: a long-half-life lipoglycopeptide","volume":"61","author":"LD Saravolatz","year":"2015","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"pone.0260539.ref012","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"DL Stevens","year":"2014","journal-title":"Clinical infectious diseases"},{"issue":"3","key":"pone.0260539.ref013","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"C Liu","year":"2011","journal-title":"Clinical infectious diseases"},{"issue":"10","key":"pone.0260539.ref014","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"A Liberati","year":"2009","journal-title":"Journal of clinical epidemiology"},{"key":"pone.0260539.ref015","unstructured":"Higgins JP. Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration. www.cochrane-handbook.org. 2011."},{"issue":"4","key":"pone.0260539.ref016","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"N Mantel","year":"1959","journal-title":"Journal of the national cancer institute"},{"issue":"3","key":"pone.0260539.ref017","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"R DerSimonian","year":"1986","journal-title":"Controlled clinical trials"},{"issue":"7109","key":"pone.0260539.ref018","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"M Egger","year":"1997","journal-title":"Bmj"},{"issue":"11","key":"pone.0260539.ref019","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1086\/429914","article-title":"Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria","volume":"40","author":"ME Stryjewski","year":"2005","journal-title":"Clinical infectious diseases"},{"issue":"3","key":"pone.0260539.ref020","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1128\/AAC.50.3.862-867.2006","article-title":"Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study","volume":"50","author":"ME Stryjewski","year":"2006","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"11","key":"pone.0260539.ref021","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1086\/587896","article-title":"Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms","volume":"46","author":"ME Stryjewski","year":"2008","journal-title":"Clinical infectious diseases"},{"issue":"1","key":"pone.0260539.ref022","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/ciq031","article-title":"Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens","volume":"52","author":"E Rubinstein","year":"2011","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"pone.0260539.ref023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-14-289","article-title":"A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study","volume":"14","author":"ME Stryjewski","year":"2014","journal-title":"BMC infectious diseases"},{"key":"pone.0260539.ref024","unstructured":"A phase 3 Telavancin staphylococcus aureus (S. aureus) Bacteremia Trial (identifier NCT02208063), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02208063."},{"issue":"3","key":"pone.0260539.ref025","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1086\/427283","article-title":"Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens","volume":"40","author":"I Raad","year":"2005","journal-title":"Clinical infectious diseases"},{"issue":"23","key":"pone.0260539.ref026","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"HW Boucher","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"pone.0260539.ref027","first-page":"ofy331","volume-title":"Open forum infectious diseases","author":"U Rappo","year":"2019"},{"issue":"23","key":"pone.0260539.ref028","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","article-title":"Single-dose oritavancin in the treatment of acute bacterial skin infections","volume":"370","author":"GR Corey","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"pone.0260539.ref029","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","article-title":"Single-dose oritavancin versus 7\u201310 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study","volume":"60","author":"GR Corey","year":"2015","journal-title":"Clinical Infectious Diseases"},{"issue":"8","key":"pone.0260539.ref030","doi-asserted-by":"crossref","first-page":"e41870","DOI":"10.1371\/journal.pone.0041870","article-title":"Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis","volume":"7","author":"KA Polyzos","year":"2012","journal-title":"PLoS One"},{"key":"pone.0260539.ref031","first-page":"349","volume-title":"InMayo Clinic Proceedings","author":"KZ Vardakas","year":"2012"},{"key":"pone.0260539.ref032","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3389\/fphar.2016.00330","article-title":"Systematic review and meta-analysis of the efficacy and safety of telavancin for treatment of infectious disease: are we clearer?","volume":"7","author":"J Chuan","year":"2016","journal-title":"Frontiers in pharmacology"},{"issue":"4","key":"pone.0260539.ref033","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cmi.2017.08.028","article-title":"Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis","volume":"24","author":"R Agarwal","year":"2018","journal-title":"Clinical Microbiology and Infection"},{"key":"pone.0260539.ref034","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/IDR.S25930","article-title":"Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumonia","volume":"7","author":"E Rubinstein","year":"2014","journal-title":"Infection and drug resistance"},{"issue":"6","key":"pone.0260539.ref035","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.amjsurg.2008.05.012","article-title":"Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures","volume":"197","author":"SE Wilson","year":"2009","journal-title":"The American journal of surgery"},{"issue":"8","key":"pone.0260539.ref036","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1185\/03007995.2015.1058248","article-title":"Comparative efficacy of antibiotics for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a systematic review and network meta-analysis","volume":"31","author":"H Thom","year":"2015","journal-title":"Current medical research and opinion"},{"issue":"10","key":"pone.0260539.ref037","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1128\/AAC.00231-09","article-title":"Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia","volume":"53","author":"CM Rubino","year":"2009","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"pone.0260539.ref038","unstructured":"Oritavancin: Highlights of prescribing information. 2014. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206334s000lbl.pdf"},{"issue":"1","key":"pone.0260539.ref039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40121-016-0103-4","article-title":"Oritavancin: a new lipoglycopeptide antibiotic in the treatment of Gram-positive infections","volume":"5","author":"KD Brade","year":"2016","journal-title":"Infectious diseases and therapy"},{"issue":"suppl_3","key":"pone.0260539.ref040","doi-asserted-by":"crossref","first-page":"S214","DOI":"10.1093\/cid\/cir920","article-title":"Oritavancin: mechanism of action","volume":"54","author":"GG Zhanel","year":"2012","journal-title":"Clinical infectious diseases"},{"issue":"11","key":"pone.0260539.ref041","doi-asserted-by":"crossref","first-page":"e0187792","DOI":"10.1371\/journal.pone.0187792","article-title":"Comparative efficacy and safety of antibiotics used to treat acute bacterial skin and skin structure infections: results of a network meta-analysis","volume":"12","author":"JF Guest","year":"2017","journal-title":"PloS one"},{"issue":"4","key":"pone.0260539.ref042","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cmi.2017.07.028","article-title":"Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin-and vancomycin-containing regimen","volume":"24","author":"BJ Werth","year":"2018","journal-title":"Clinical Microbiology and Infection"},{"issue":"1","key":"pone.0260539.ref043","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/jcpt.12580","article-title":"Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin","volume":"43","author":"JM Steele","year":"2017","journal-title":"Journal of clinical pharmacy and therapeutics"},{"issue":"10","key":"pone.0260539.ref044","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/497271","article-title":"Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections","volume":"41","author":"LE Jauregui","year":"2005","journal-title":"Clinical infectious diseases"},{"issue":"Issue 5","key":"pone.0260539.ref045","first-page":"545","article-title":"Dunne, Sailaja Puttagunta, Philip Giordano, Dainis Krievins, Michael Zelasky, James Baldassarre, A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection","volume":"Volume 62","author":"W Michael","year":"2016","journal-title":"Clinical Infectious Diseases"},{"issue":"suppl_2","key":"pone.0260539.ref046","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1093\/cid\/civ536","article-title":"Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality","volume":"61","author":"MK Lacy","year":"2015","journal-title":"Clinical Infectious Diseases"},{"issue":"suppl_1","key":"pone.0260539.ref047","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1093\/cid\/cit614","article-title":"Methicillin-resistant Staphylococcus aureus therapy: past, present, and future","volume":"58","author":"KA Rodvold","year":"2014","journal-title":"Clinical infectious diseases"},{"issue":"10","key":"pone.0260539.ref048","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3390\/antibiotics9100700","article-title":"Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care","volume":"9","author":"L Ajaka","year":"2020","journal-title":"Antibiotics"},{"issue":"4","key":"pone.0260539.ref049","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the treatment of different gram-positive infections: a real-life experience","volume":"51","author":"E Bouza","year":"2018","journal-title":"International journal of antimicrobial agents"},{"key":"pone.0260539.ref050","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","article-title":"Multicenter clinical experience of real life Dalbavancin use in gram-positive infections","volume":"81","author":"S Wunsch","year":"2019","journal-title":"International Journal of Infectious Diseases"},{"issue":"5","key":"pone.0260539.ref051","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02280-18","article-title":"Safety and efficacy of prolonged use of dalbavancin in bone and joint infections","volume":"63","author":"L Morata","year":"2019","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"3","key":"pone.0260539.ref052","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2018.10.007","article-title":"Dalbavancin for the management of gram-positive osteomyelitis: effectiveness and potential utility","volume":"93","author":"TA. Almangour","year":"2019","journal-title":"Diagn.Microbiol.Infect.Dis"},{"issue":"4","key":"pone.0260539.ref053","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jsps.2020.02.007","article-title":"Dalbavancin versus standard of care for the treatment of osteomyelitis in adults: a retrospective matched cohort study","volume":"28","author":"TA Almangour","year":"2020","journal-title":"Saudi Pharmaceutical Journal"},{"issue":"2","key":"pone.0260539.ref054","first-page":"77","article-title":"Use of oritavancin (novel new lipoglycopeptide) in the treatment of prosthetic joint infections (PJI): a possible alternative novel approach to a difficult problem","volume":"17","author":"SJ Antony","year":"2017","journal-title":"Infectious Disorders-Drug Targets (Formerly Current Drug Targets-Infectious Disorders)"},{"key":"pone.0260539.ref055","first-page":"ofv156","volume-title":"Open forum infectious diseases","author":"JA Johnson","year":"2015"},{"key":"pone.0260539.ref056","doi-asserted-by":"crossref","first-page":"106069","DOI":"10.1016\/j.ijantimicag.2020.106069","article-title":"Treatment of osteoarticular, cardiovascular, intravascular catheter-related, and other complicated infections with dalbavancin and oritavancin: a systematic review","volume":"27","author":"G Thomas","year":"2020","journal-title":"International Journal of Antimicrobial Agents"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0260539","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T18:35:49Z","timestamp":1638210949000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0260539"}},"subtitle":[],"editor":[{"given":"Ali","family":"Rostami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,11,29]]},"references-count":56,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0260539","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,29]]}}}